Cisapride in chronic dyspepsia: results of a double-blind, placebo-controlled trial.
The efficacy and tolerability of cisapride in chronic dyspepsia was evaluated in a randomized, double-blind, placebo-controlled study. After 4 weeks' treatment with oral cisapride 10 mg three times daily (n = 14), bloating and epigastric discomfort were significantly reduced compared with placebo (n = 15; p < 0.05). Moreover, the global response to treatment was excellent or good in 71.4% of patients in the cisapride group versus 20.0% with placebo. No significant side effects were observed. It is concluded that cisapride is an effective and well-tolerated treatment for chronic dyspepsia.
Chung
J M
JM
Dept. of Internal Medicine, School of Medicine, Kyungbook National University, Taegu, Korea.
D000293:Adolescent; D000328:Adult; D002908:Chronic Disease; D020117:Cisapride; D004311:Double-Blind Method; D004415:Dyspepsia / Q000188:drug therapy* / Q000503:physiopathology; D005260:Female; D005769:Gastrointestinal Motility / Q000187:drug effects*; D006801:Humans; D008297:Male; D010880:Piperidines / Q000627:therapeutic use*; D012720:Severity of Illness Index; D016896:Treatment Outcome
D010880:Piperidines; D020117:Cisapride